Larimar Therapeutics Inc (LRMR)
7.035
-0.26
(-3.50%)
USD |
NASDAQ |
Jun 25, 16:00
7.035
0.00 (0.00%)
After-Hours: 20:00
Larimar Therapeutics Cash from Financing (Quarterly): 162.15M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 162.15M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.03M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | -0.316M |
| September 30, 2022 | 75.57M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | 19.88M |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.242M |
| September 30, 2020 | -0.135M |
| June 30, 2020 | 83.90M |
| March 31, 2020 | 9.577M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.316M
Minimum
Dec 2022
162.15M
Maximum
Mar 2024
20.64M
Average
--
Median
Mar 2021
Cash from Financing (Quarterly) Benchmarks
| Biogen Inc | -439.60M |
| Eli Lilly and Co | -311.30M |
| PTC Therapeutics Inc | 0.54M |
| Design Therapeutics Inc | 0.02M |
| CEL-SCI Corp | 6.596M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.41M |
| Cash from Investing (Quarterly) | -68.36M |
| Free Cash Flow | -36.32M |
| Free Cash Flow Per Share (Quarterly) | -0.1944 |
| Free Cash Flow Yield | -11.15% |